Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
In a recent transaction, BP4 S.r.l., a significant shareholder of Milestone Scientific Inc. (AMEX:NYSE:MLSS), sold 23,797 shares of the company’s common stock. The shares were sold at an average price of $0.902 each, bringing the total value of the transaction to $21,464. Following this sale, BP4 S.r.l. retains ownership of 9,457,239 shares in the company. The transaction was executed on June 11, 2025, as per the filing with the Securities and Exchange Commission.According to InvestingPro data, MLSS currently trades at a high Price/Book multiple of 15.5x, with analyst price targets ranging from $1.25 to $3.00. The company maintains a Fair financial health score, though analysts don’t expect profitability this year. Get access to 12+ additional exclusive InvestingPro Tips and comprehensive analysis for MLSS through the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Milestone Scientific Inc. reported a strong financial standing, ending the fourth quarter with $3.3 million in cash and no outstanding debt. Analysts at Benchmark have reiterated their Buy rating for the company, maintaining a price target of $1.25, based on projected revenue growth. This endorsement comes as Milestone Scientific continues to expand its Medicare market segment for pain management through its CompuFlo System, which has secured coverage from three out of twelve Medicare Administrative Contractors. The company aims to further its reach by obtaining coverage from the remaining nine MACs and pursuing reimbursement from private payors, potentially opening a market of nine million procedures.
Additionally, Milestone Scientific has appointed Shanth Thiyagalingam to its Board of Directors to support its growth strategies. Thiyagalingam brings over two decades of experience in the medical device and pharmaceutical sectors, with a strong background in commercial scaling and strategic execution. His appointment is expected to enhance the company’s market presence and drive expansion. The company is also leveraging favorable Medicare Part B payment rates and a Federal Supply Schedule contract to increase adoption of its technologies. These developments reflect Milestone Scientific’s ongoing efforts to strengthen its position in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.